What does nucynta ER AG — product revenues, net mean?

This metric represents the net revenue generated from the sale of the Nucynta ER product line, reflecting the total sales after accounting for returns, rebates, and other adjustments. It serves as a key indicator of the product's market adoption and commercial performance within the company's specialty pharmaceutical portfolio. Monitoring this revenue stream helps investors assess the product's contribution to overall top-line growth and its lifecycle stage in the chronic pain management market.

Collegium Pharmaceutical, Inc. (COLL) Nucynta ER AG — Product revenues, net

Screener

Other product segments

Belbuca

$57.67M+9.6%

Jornay PM

$46.06M+41.2%

Xtampza ER

$45.01M—

Nucynta ER

$15.72M-21.2%

Symproic and other

$14.45M—

Nucynta IR

$14.36M-45.8%

Azstarys

$12.91M—

Symproic

$3.02M-18.9%

Nucynta IR AG

$2.36M—

Similar metrics at other companies

VRTXProduct revenues, net — Product revenues, net

$3.33B+13.2%

VRTXOther CF product revenues — Product revenues, net

$135.9M-12.5%

VRTXOther revenues — Product revenues, net

$0-100%

VRTXALYFTREK — Product revenues, net

$573.6M+266%

VRTXCASGEVY — Product revenues, net

$76.4M+151%

VRTXJOURNAVX — Product revenues, net

$49.6M+313%

Other financials

Income statement

See full

Revenue$199.9M+6.3%

Gross profit$110.3M+1.8%

Operating income$3.7M-89.5%

Net income-$15.1M-226%

EPS (diluted)-$0.46-235%

Balance sheet

See full

Cash & equivalents$150.4M+8.8%

Total debt$5.0M-19.8%

Total equity$311.9M+34.3%

Total assets$2.1B+34.1%

Cash flow

See full

Operating cash flow$71.3M-1.5%

CapEx$496.0K+663%

Free cash flow$70.8M-2.1%

Valuation

See full

Market cap$944.15M-1.3%

Enterprise value$798.74M-3.1%

P/E19.7×-6.7×

P/S1.2×-0.2×

Profitability

See full

Gross margin60%+3.3pp

Operating margin19.5%+1.1pp

Net margin5.9%+0.8pp

FCF margin40.6%+10.8pp

Returns & leverage

See full

Return on equity17.6%+1.4pp

Debt / equity0×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:34 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053851

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Jornay PM	46,058	32,626	84,951	61,165
Nucynta IR	14,356	26,501	40,434	53,918
Nucynta ER	15,723	19,946	33,957	39,632
Azstarys	12,910	—	12,910	—
Symproic	3,020	3,722	7,213	6,537
Nucynta ER AG	2,775	—	4,221	—
Nucynta IR AG	2,361	—	3,619	—
Total product revenues, net	$199,878	$188,000	$393,398	$365,757

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s nucynta ER AG — product revenues, net?: Collegium Pharmaceutical, Inc. (COLL) reported nucynta ER AG — product revenues, net of $2.78M in Q2 2026.
What does nucynta ER AG — product revenues, net mean?: This metric represents the net revenue generated from the sale of the Nucynta ER product line, reflecting the total sales after accounting for returns, rebates, and other adjustments. It serves as a key indicator of the product's market adoption and commercial performance within the company's specialty pharmaceutical portfolio. Monitoring this revenue stream helps investors assess the product's contribution to overall top-line growth and its lifecycle stage in the chronic pain management market.